[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Salerno\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":212},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,63,98,127,155,176],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100638763","smoking-cessation-with-wearables-to-improve-general-oral-health-and-quality-of-life-100638763",false,"NCT07593742","Smoking Cessation With Wearables to Improve General, Oral Health and Quality of Life","Smoking Cessation Programme in Telerehabilitation Assisted by Telemonitoring With Non-Invasive Wearable Devices for the Improvement of Oral Health, General Health and Quality of Life","Wear-Smile","Inclusion Criteria:\n\n* Subjects who smoke ≥ 5 cigarettes per day (traditional or equivalent in nicotine content in non-combustible tobacco or liquid\u002Fvape), regardless of the severity of nicotine dependence\n* Subjects ≥ 18 years of age\n* Ability and willingness to provide informed consent or presence of a legal representative who consents\n* Subjects in possession of home medical devices for measuring cardiopulmonary parameters (sphygmomanometer and pulse oximeter) (requirement applicable to participants assigned to the control group)\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Pregnant or breastfeeding women\n* Subjects with a remote or current history of using smoking cessation methods\n* Subjects with acute dependence on alcohol or other substances of abuse other than nicotine\n* Pathologies with advanced neurocognitive degeneration\n* Unstable psychiatric conditions (subjects with active suicidal ideation, hospitalization for psychiatric reasons and\u002For changes in psychiatric medication for less than 3 months)\n* Inability or refusal to sign informed consent\n* Inability to access the integrated telemedicine platform and\u002For wearable remote monitoring devices (requirement applicable to participants assigned to the experimental group)","ALL","18 Years",{"count":20,"type":21},102,"ESTIMATED","INTERVENTIONAL",[24],"NA","Tobacco smoking remains one of the leading preventable causes of disease, disability, and premature death worldwide. According to the World Health Organization, tobacco use is responsible for more than eight million deaths each year globally, including deaths caused by direct smoking and exposure to secondhand smoke. Smoking is a major risk factor for a wide range of chronic diseases, including cardiovascular diseases, chronic respiratory diseases, several types of cancer, and numerous oral health conditions. In addition to systemic effects, tobacco use is strongly associated with oral potentially malignant disorders and oral squamous cell carcinoma, representing a significant burden for public health systems.\n\nDespite the well-documented health risks, smoking cessation remains difficult for many individuals due to the addictive properties of nicotine and the complex behavioral and psychological components associated with tobacco dependence. Multimodal smoking cessation programs that combine behavioral counseling, psychological support, and continuous monitoring have been shown to increase the likelihood of successful cessation. However, access to these programs may be limited by logistical barriers, including geographic distance, time constraints, and limited availability of specialized services.\n\nIn recent years, telemedicine and digital health technologies have emerged as promising tools to support healthcare delivery and improve access to treatment programs. Telemedicine platforms allow remote interaction between patients and healthcare professionals, facilitating communication, follow-up, and monitoring of patients over time. Additionally, wearable devices and remote monitoring systems enable the collection of physiological and behavioral data outside traditional clinical settings, providing clinicians with valuable information to support personalized interventions.\n\nThe aim of this study is to evaluate the effectiveness and feasibility of a smoking cessation program delivered through a telerehabilitation model supported by an integrated telemedicine platform and wearable remote monitoring devices. The program is designed to support individuals who smoke tobacco products, including both combustible tobacco and alternative nicotine-containing products, by providing behavioral and psychological interventions combined with continuous remote monitoring.\n\nParticipants enrolled in the study will be assigned to one of two groups. The intervention group will participate in a telerehabilitation program delivered through a dedicated telemedicine platform. This program will include structured behavioral and psychological treatment sessions aimed at supporting smoking cessation, along with remote monitoring through non-invasive wearable devices that allow healthcare professionals to track selected physiological parameters and patient engagement during the treatment process.\n\nThe control group will receive the same multimodal behavioral and psychological treatment program but delivered through conventional rehabilitation methods without the use of telemedicine technologies or wearable monitoring devices.\n\nBy comparing these two approaches, the study aims to explore whether the integration of telemedicine and wearable technologies into smoking cessation programs may improve patient engagement, facilitate monitoring, and potentially enhance the effectiveness of behavioral interventions aimed at reducing tobacco use. The findings of this study may contribute to the development of innovative digital health strategies for smoking cessation and provide evidence to support the integration of telemedicine into addiction treatment and preventive healthcare programs.",[27,28,29,30,31,32,33,34,35],"Smoking ( Cigarette)","Smoking (Tobacco) Addiction","Smoking Behaviors","Smoking Cessation","Smoking Dependence","Smoking Addiction","Smoking Cessation Intervention","Smoking E-cigarette","Smoking Abstinence",[37,38,39,40,41,42,43,44,45,46,47,48,49,50],"Smoking","Smoking cessation","Smoking addiction","Tobacco","Wearable device","Telerehabilitation","Oral Health","Periodontal Health","General Health","Quality of life","Periodontal disease","E-cigarette","Heat not burn tobacco","Smoking abstinence","NOT_YET_RECRUITING","2026-05-11",{"date":54,"type":55},"2026-05-18","ACTUAL",{"date":57,"type":21},"2026-06-01",{"date":59,"type":21},"2027-11-01",{"name":61,"class":62},"University of Salerno","OTHER",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100636079","high-technology-telerehabilitation-for-the-treatment-of-the-fragile-patient-100636079","NCT07561021","High-technology TeleRehabilitation for the Treatment of the FRAgile Patient","TeleRiab4Fra","Inclusion Criteria:\n\n* Age 65 years or older.\n* Diagnosis of chronic heart failure for at least 6 months, on stable optimal medical therapy for at least 1 month, regardless of systolic function classification (HFrEF, HFmrEF, or HFpEF), and in NYHA class I-III.\n* Pre-frailty or frailty documented by validated instruments, defined by at least one of the following: Fried phenotype: pre-frailty (1-2 criteria) or frailty (3 or more criteria); Italian Frailty Index (IFI): score ≥1;\n\nShort Physical Performance Battery (SPPB):\n\ntotal score 5-9\u002F12, consistent with functional frailty; or total score 10\u002F12, consistent with pre-frailty if the reduction is attributable to the sit-to-stand test, as documented in the case report form.\n\n* Ability to provide written informed consent, or availability of a legally authorized representative when applicable.\n* Availability of a caregiver, when required for participation in the rehabilitation program.\n\nExclusion Criteria:\n\n* Age younger than 65 years.\n* NYHA class IV and\u002For high likelihood of heart transplantation or ventricular assist device (VAD) implantation within 6 months after screening.\n* Absence of pre-frailty\u002Ffrailty, defined as:\n\nFried phenotype = 0 criteria, and IFI = 0, and SPPB ≥ 11\u002F12 (or 10\u002F12 without evidence of impairment in the sit-to-stand component according to the predefined criterion).\n\n* Severe renal impairment (estimated glomerular filtration rate eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²) or dialysis.\n* Inability to walk independently, even with assistive devices. SPPB total score \\\u003C5\u002F12, indicating severe functional impairment not compatible with safe execution of the study protocol, regardless of IFI or Fried criteria.\n* Other serious diseases substantially limiting life expectancy (for example, end-stage cancer or end-stage lung disease).\n* Severe visual impairment preventing completion of study procedures even with caregiver support and reasonable accommodations.\n* Current or suspected pregnancy.","65 Years",{"count":72,"type":21},70,[24],"The aim of this randomized controlled clinical trial is to evaluate the efficacy of an 8-week sensorimotor and cognitive telerehabilitation program in frail and pre-frail older adults with stable chronic heart failure. The study will compare a synchronous telerehabilitation intervention with a caregiver-supervised home exercise program. The primary question is whether telerehabilitation improves functional capacity, measured by change in peak oxygen uptake (VO₂peak) on cardiopulmonary exercise testing, more than the control intervention. A key secondary question is whether telerehabilitation improves frailty status, measured by the Italian Frailty Index (IFI), compared with the control group. Secondary outcomes include quality of life, physical performance, cognitive function, treatment adherence, caregiver burden and stress, and selected biomarkers related to heart failure and frailty. Participants will undergo baseline and follow-up clinical, functional, cognitive, and laboratory assessments and will be followed for up to 24 weeks.",[76,77,78],"Heart Failure","Prefrail Elderly","Frail Elderly Syndrome",[80,81,82,83,84,85,86,87,88,89],"Chronic Heart Failure","Cardiac Rehabilitation","Tele-rehabilitation","Telemedicine","Exercise Training","Remote Monitoring","mHealth","Wearable Sensors","Home-based Rehabilitation","Digital Health","2026-05-01",{"date":92,"type":55},"2026-05-07",{"date":94,"type":21},"2026-05-15",{"date":96,"type":21},"2027-03-15",{"name":61,"class":62},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100579204","efficacy-and-safety-of-transcranial-direct-current-stimulation-in-multiple-system-atrophy-cerebellar-variant-100579204","NCT06821256","Efficacy and Safety of Transcranial dIrect Current stiMulation in Multiple System Atrophy-Cerebellar Variant","Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) on Cerebellar Symptoms in Multiple System Atrophy-Cerebellar Variant (MSA-C) (STIM-MSA)","STIM-MSA","Inclusion Criteria:\n\n* Multiple system atrophy cerebellar variant according with the Movemente Disorder Society criteria (Wenning et al 2022)\n* Ability to walk either indipendently or with a minimum support\n\nExclusion Criteria:\n\n* Presence of electrical stimulators (for example, pacemaker, Deep Brain Stimulation, DBS)\n* Difficult in understanding Italian language\n* Presence of severe sensory deficits (for example, visual or hearing impairments)\n* History of drug abuse\n* History of severe psychiatric disorders\n* History of transient ischemic attacks\n* Cortical or sub-cortical vascular lesions\n* Seizures or severe heart problems and previous neurosurgical operations\n* Pregnancy","40 Years","90 Years",{"count":109,"type":21},30,[24],"This is a double-blind, randomized, sham-controlled clinical trial that aim to verify the safety and the efficacy of anodal transcranial direct current stimulation (tDCS) cerebellar symptoms in Multiple System Atrophy type C (MSA).",[113],"Multiple System Atrophy - Cerebellar Subtype (MSA-C)",[115,116],"Multiple System Atrophy type C (MSA-C),","Transcranial direct current stimulation (tDCS)","RECRUITING","2026-04-28",{"date":120,"type":55},"2026-04-29",{"date":122,"type":55},"2023-07-03",{"date":124,"type":21},"2027-12",{"name":61,"class":62},1,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":137,"studyType":138,"phases":4,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":126},"100561353","transcatheter-aortic-valve-replacement-in-severe-low-flow-low-gradient-aortic-stenosis-100561353","NCT06589063","Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis","Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis: the Multicenter LOW-TAVR Registry","LOW-TAVR","Inclusion Criteria:\n\n* LFLG-AS diagnosis according to current European Society of Cardiology guidelines\n* Age 18 years or older\n* Written informed consent\n\nExclusion Criteria:\n\n* LFLG-AS pseudo-severe or non-confirmed severe aortic stenosis\n* LFLG-AS referred for medical treatment or undergoing surgery",{"count":136,"type":21},1350,"5 Years","OBSERVATIONAL","LOW-TAVR is a real-world, retrospective and prospective, multicenter Italian registry aimed at evaluating the characteristics and clinical outcomes of patients with severe low flow, low gradient aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) and, in particular:\n\n* risk factors\n* gender differences\n* comorbidities\n* pharmacological treatment\n* TAVR procedural characteristics\n* periprocedural and in-hospital complications\n* clinical outcome at 30-day, 1-year, 2-year and 5-year follow-up",[141],"Low Flow, Low Gradient Aortic Stenosis",[143,144,145,146],"aortic stenosis","transcatheter aortic valve replacement","clinical outcomes","interventional cardiology","2026-04-01",{"date":149,"type":55},"2026-04-07",{"date":151,"type":55},"2024-03-01",{"date":153,"type":21},"2037-12-31",{"name":61,"class":62},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":126},"100594752","effectiveness-of-a-cardiac-telerehabilitation-program-in-chronic-heart-failure-100594752","NCT07023536","Effectiveness of a Cardiac Telerehabilitation Program in Chronic Heart Failure","Evaluation of the Effectiveness of a Cardiac Telerehabilitation Program in Chronic Heart Failure","TELEREHAB-HF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of chronic heart failure for at least 6 months, with stable optimal medical therapy for at least 1 month\n* New York Heart Association (NYHA) functional class I, II, or III\n* Hospitalization or outpatient visit requiring intravenous therapy (diuretics, vasodilators, or inotropes) within the past 12 months\n* Ability to provide informed consent or presence of a legal representative\n* Digital literacy of the patient and\u002For caregiver\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy\n* NYHA class IV heart failure\n* Severe renal insufficiency (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²) or on dialysis\n* Other serious illnesses significantly limiting life expectancy (e.g., end-stage cancer, advanced pulmonary disease)",{"count":164,"type":21},205,"The goal of this observational study is to evaluate whether a home-based cardiac tele-rehabilitation program can improve functional capacity in adults (18 years and older) with chronic heart failure. The main questions it aims to answer are:\n\nDoes tele-rehabilitation improve peak oxygen uptake (VO₂ max) compared to standard in-hospital rehabilitation? Does it improve cardiac function, exercise tolerance, biochemical markers, and quality of life? Are functional gains maintained at 24 weeks? Researchers will compare patients who opt for tele-rehabilitation using wearable devices and a remote monitoring platform with those undergoing standard in-person rehabilitation. Participants will follow an 8-week individualized training program and undergo assessments at baseline, 4, 8, 16, and 24 weeks.",[76],[80,81,82,83,84,85,86,87,88,89],"2026-03-09",{"date":170,"type":55},"2026-03-11",{"date":172,"type":55},"2025-06-10",{"date":174,"type":21},"2026-12-01",{"name":61,"class":62},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":126},"100586000","ai-based-monitoring-system-for-chronic-heart-failure-with-advanced-wearable-and-mini-invasive-devices-100586000","NCT06909682","AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices","Smart Monitoring and Analysis System Based on Artificial Intelligence for Patients With Chronic Heart Failure Using Advanced Mini-Invasive and Wearable Medical Devices","SMART-CARE","Inclusion Criteria\n\n* Age ≥ 18 years (adults of any sex)\n* Confirmed diagnosis of chronic heart failure (CHF) for at least 6 months prior to screening\n* Stable on optimized heart failure therapy for at least one month before enrollment\n* Any left ventricular ejection fraction (LVEF) classification, including:\n\n  * Heart Failure with Reduced Ejection Fraction (HFrEF)\n  * Heart Failure with Mid-Range Ejection Fraction (HFmrEF)\n  * Heart Failure with Preserved Ejection Fraction (HFpEF)\n* NYHA Functional Class I, II, or III\n* History of at least one hospital admission or outpatient visit in the past 12 months requiring intravenous (IV) diuretics, vasodilators, or inotropes for CHF exacerbation\n* Ability to provide written informed consent or availability of a legally authorized representative Exclusion Criteria\n* NYHA Functional Class IV or anticipated heart transplant or ventricular assist device (VAD) implantation within 6 months of screening\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or dialysis dependence\n* Terminal comorbidities (e.g., advanced cancer, end-stage pulmonary disease) significantly limiting life expectancy\n* Pregnancy\n* Presence of skin conditions or allergies preventing prolonged use of a wearable device\n* Inability to comply with study procedures (e.g., cognitive impairment, significant psychiatric disorders)","19 Years",{"count":164,"type":21},"The goal of this observational, multicenter study is to evaluate whether AI-driven remote monitoring using a mini-invasive wearable device can improve clinical outcomes in adult patients (≥18 years) with chronic heart failure (CHF).\n\nThe main questions it aims to answer are:\n\n* Can continuous remote monitoring reduce hospital admissions (emergency visits and hospitalizations) by 20% compared to standard care?\n* Does wearable-based remote monitoring improve functional, biochemical, and instrumental parameters in CHF patients? Researchers will compare patients using the wearable device (intervention group) to those receiving standard clinical follow-up (control group) to assess whether AI-driven monitoring leads to fewer hospitalizations, better disease management, and improved quality of life.\n\nParticipants will:\n\n* Wear the EmbracePlus (Empatica Inc.) device continuously for six months (intervention group only).\n* Have their biometric data (SpO₂, HRV, EDA, respiratory rate, temperature, sleep quality) monitored remotely.\n* Receive automated alerts and teleconsultations if abnormal physiological changes are detected.\n* Attend scheduled follow-up visits (remote and in-person) for clinical evaluation and treatment adjustments.\n\nThe study aims to provide real-world evidence on whether integrating wearable health technology with AI analytics can enhance CHF management and improve patient outcomes.",[80,188,189,190,191],"Cardiovascular Diseases","Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Preserved Ejection Fraction (HFPEF)","Congestive Heart Failure Chronic",[193,194,195,196,197,198,199,200,201,202,203,204,205],"Wearable Medical Devices","Remote Patient Monitoring","Artificial Intelligence in Cardiology","Smart Wearables for Healthcare","Observational Study in Heart Failure","AI-Based Predictive Modeling","Telemedicine in Heart Failure","Non-Invasive Health Monitoring","Personalized Medicine for CHF","Quality of Life Improvement in Heart Failure","Heart Failure Readmission Prevention","Telehealth in Chronic Disease Management","Digital Health Solutions for Heart Disease",{"date":170,"type":55},{"date":208,"type":55},"2025-08-01",{"date":210,"type":21},"2027-02-02",{"name":61,"class":62},""]